Hyaluronic Acid Dermal Filler 20mg/ml with CE Certification | Injectable Gel for Wrinkle Reduction in Europe
May 1, 2026
Introduction: CE-Certified Dermal Filler Formulated for the European Aesthetic Market
Jinan Fushunchang International Trade Co., Ltd. (Fosyderm), an ISO-certified manufacturer of professional aesthetic products since 2005, proudly presents its 20mg/ml Hyaluronic Acid Dermal Filler to the European market. This advanced injectable gel is manufactured in compliance with EU Medical Device Regulation (MDR) 2017/745 standards and is suitable for CE marking pathways, making it an accessible option for aesthetic clinics, dermatology practices, and medical spas across the European Union.
Fosyderm's European offering addresses the continent's growing demand for high-quality, cost-effective dermal fillers. With aesthetic procedures in Europe increasing by approximately 8% annually according to the International Society of Aesthetic Plastic Surgery (ISAPS), clinics from Germany to Spain are actively seeking reliable supply partners who can deliver consistent product quality with competitive pricing — precisely the value proposition Fosyderm brings to the European market.
Product Overview: Three Models for Tailored Aesthetic Outcomes
The 20mg/ml Hyaluronic Acid Dermal Filler is available in three distinct models — ultra3, ultra4, and voluma — each formulated with cross-linked HA technology to provide specific rheological properties suited to different anatomical regions and injection depths:
- Ultra3: Medium-density formulation optimized for moderate wrinkles, nasolabial folds, and perioral lines. Ideal for patients seeking subtle yet visible correction.
- Ultra4: Higher-density formulation designed for deep wrinkle correction, including marionette lines and glabellar folds. Provides robust structural support.
- Voluma: High G' (elastic modulus) formulation engineered for mid-face volumization, cheek augmentation, and chin contouring. Delivers lift and projection comparable to premium European HA fillers.
Clinical Performance and Patient Outcomes
European aesthetic practitioners value predictability, safety, and patient satisfaction above all else. Fosyderm's cross-linked HA filler delivers on all three fronts:
| Clinical Parameter | Performance Data |
|---|---|
| Duration of Effect | 9–12 months, consistent across all three models |
| Recovery Time | 1–2 days; most patients resume normal activities within 24 hours |
| Adverse Event Profile | No significant side effects; mild transient erythema/edema at injection site |
| Patient Satisfaction | High satisfaction rates for natural-looking results and comfortable injection experience |
| Gel Cohesion | Superior cohesivity prevents migration and ensures even tissue distribution |
The filler's smooth, homogeneous gel consistency facilitates precise injection control, allowing European practitioners to achieve consistent aesthetic outcomes across diverse patient populations. The cross-linking technology ensures gel stability and resistance to enzymatic degradation, contributing to the product's 9–12 month duration profile.
Regulatory Alignment with EU MDR 2017/745
Fosyderm's manufacturing facility operates under quality management systems aligned with the requirements of EU MDR 2017/745, which governs the safety and performance of medical devices — including dermal fillers — placed on the European market. Key regulatory considerations include:
- Biocompatibility Testing: Comprehensive ISO 10993 biocompatibility assessment confirming the filler's safety profile for intradermal and subcutaneous administration.
- Sterility Assurance: Validated aseptic manufacturing processes with terminal sterilization, meeting European Pharmacopoeia standards for sterility (Ph. Eur. 2.6.1).
- Traceability: Full batch-level traceability from raw material sourcing through finished product release, supporting EU Unique Device Identification (UDI) requirements.
- Clinical Evaluation: Ongoing post-market clinical follow-up (PMCF) activities to continuously monitor safety and performance in real-world European clinical settings.
OEM and Private Label Opportunities for European Distributors
Fosyderm offers comprehensive OEM manufacturing services tailored to the European market. EU-based distributors and aesthetic brands can leverage private-label production to launch proprietary dermal filler lines without investing in manufacturing infrastructure. With minimum order quantities starting at just one box, rapid 5–7 day international shipping, and flexible payment terms including L/C, T/T, and Western Union, Fosyderm provides an accessible entry point for European businesses seeking to expand their injectable portfolios.
The company's 5,000-unit weekly supply capacity ensures reliable fulfillment for distributors of all sizes, from boutique aesthetic clinics to national-level medical device wholesalers operating across the Schengen Area and beyond.
About Jinan Fushunchang International Trade Co., Ltd.
Established in 2005 and headquartered in Jinan, China, Jinan Fushunchang International Trade Co., Ltd. (brand: Fosyderm) operates as both a manufacturer and trading company specializing in professional aesthetic injectables. The company employs 80–100 professionals and exports 90%–100% of its production to international markets, including a growing presence across European Union member states. With annual export revenues of $300,000–$450,000, Fosyderm is a trusted partner for aesthetic clinics, medical device distributors, and private-label brands worldwide. The company's guiding philosophy — "Natural Beauty Starts From Fosyderm Hyaluronic Acid" — reflects its enduring commitment to biocompatible, scientifically advanced aesthetic solutions.